These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15774576)

  • 1. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor.
    Johns TG; Mellman I; Cartwright GA; Ritter G; Old LJ; Burgess AW; Scott AM
    FASEB J; 2005 May; 19(7):780-2. PubMed ID: 15774576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
    Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM
    J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
    Johns TG; Perera RM; Vernes SC; Vitali AA; Cao DX; Cavenee WK; Scott AM; Furnari FB
    Clin Cancer Res; 2007 Mar; 13(6):1911-25. PubMed ID: 17363548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
    Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
    Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers.
    Kozer N; Kelly MP; Orchard S; Burgess AW; Scott AM; Clayton AH
    Biochemistry; 2011 May; 50(18):3581-90. PubMed ID: 21495621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
    Johns TG; Luwor RB; Murone C; Walker F; Weinstock J; Vitali AA; Perera RM; Jungbluth AA; Stockert E; Old LJ; Nice EC; Burgess AW; Scott AM
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15871-6. PubMed ID: 14676326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR.
    Luwor RB; Zhu HJ; Walker F; Vitali AA; Perera RM; Burgess AW; Scott AM; Johns TG
    Oncogene; 2004 Aug; 23(36):6095-104. PubMed ID: 15221011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
    Johns TG; Stockert E; Ritter G; Jungbluth AA; Huang HJ; Cavenee WK; Smyth FE; Hall CM; Watson N; Nice EC; Gullick WJ; Old LJ; Burgess AW; Scott AM
    Int J Cancer; 2002 Mar; 98(3):398-408. PubMed ID: 11920591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines.
    Hoffmann T; Hafner D; Ballo H; Haas I; Bier H
    Anticancer Res; 1997; 17(6D):4419-25. PubMed ID: 9494544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).
    Klausz K; Berger S; Lammerts van Bueren JJ; Derer S; Lohse S; Dechant M; van de Winkel JG; Peipp M; Parren PW; Valerius T
    Cancer Sci; 2011 Oct; 102(10):1761-8. PubMed ID: 21718386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
    O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA
    Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
    Udayachander M; Meenakshi A; Sivakumar N; Kumar RR; Shankar SG; Dean CJ; Modjtahedi H
    Hum Antibodies; 1999; 9(3):149-54. PubMed ID: 10690627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
    Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
    Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy.
    Gan HK; Burgess AW; Clayton AH; Scott AM
    Cancer Res; 2012 Jun; 72(12):2924-30. PubMed ID: 22659454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
    Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ
    Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.